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ABSTRACT
Recurrent malignancy remains a significant complication after allogeneic hematopoietic cell transplantation
(HCT). Efforts to decrease relapse have included donor lymphocyte infusion to stimulate donor anti-recipient
T-cell allorecognition of major and minor histocompatibility differences. Recently, alloreactive effects of donor
natural killer cell-mediated inhibitory killer immunoglobulin-like receptor (KIR) recognition of recipient
HLA-C and -B ligands have been described. We examined KIR ligand effects on risk of relapse in 1770 patients
undergoing myeloablative T-replete HCT from HLA-matched or -mismatched unrelated donors for the
treatment of myeloid and lymphoid leukemias. KIR ligands defined by HLA-B and -C genotypes were used to
determine donor-recipient ligand incompatibility or recipient lack of KIR ligand. Among HLA-mismatched
transplantations, recipient homozygosity for HLA-B or -C KIR epitopes predicted lack of KIR ligand and was
associated with a decreased hazard of relapse (hazard ratio, 0.61; 95% confidence interval, .043-0.85; P .004).
Absence of HLA-C group 2 or HLA-Bw4 KIR ligands was associated with lower hazards of relapse (hazard
ratio, 0.47; 95% confidence interval, 0.28-0.79, P .004; hazard ratio, 0.56; 95% confidence interval, 0.33-0.97;
P  .04, respectively). The decrease in hazard of relapse in patients with acute myelogenous leukemia was
similar to that in patients with chronic myelogenous leukemia and acute lymphoblastic leukemia (P  .95).
Recipient homozygosity for HLA-B or -C epitopes that define KIR ligands is likely to be a predictive factor for
leukemia relapse after myeloablative HCT from HLA-mismatched unrelated donors. This effect was not
observed in HLA-identical unrelated transplants.
© 2006 American Society for Blood and Marrow Transplantation
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KIR Ligands and HCT Relapse 829NTRODUCTION
Malignant hematologic disorders can be cured by
ematopoietic cell transplantation (HCT), and the
vailability of unrelated volunteer hematopoietic cell
onors has broadened the treatment options for many
atients who otherwise lack related donors [1-3]. Dis-
ase relapse after transplantation remains a signiﬁcant
hallenge [4-6], underscoring the importance of iden-
ifying genetic and nongenetic factors that can affect
elapse rates.
Recognition of recipient HLA ligand by donor
atural killer (NK) cell inhibitory killer immunoglob-
lin-like receptors (KIRs) has been proposed as the
asis for alloreactivity leading to a decrease in post-
ransplantation relapse and improved survival after
LA-mismatched transplantation for acute myeloge-
ous leukemia (AML) [7,8]. Initial studies predicted
onor NK alloreactivity based on a model of KIR
igand incompatibility in which donors with HLA
enotypes comprised of class I ligands for inhibitory
IR are paired with recipients with HLA genotypes
acking one or more of the class I ligands present in
he donor. Upon transfer to a recipient lacking the
ognate class I ligand, donor NK cells expressing the
elevant inhibitory KIR are released from inhibition
nd allow NK activation in a graft-versus-host (GVH)
irection. Cytotoxicity against residual host leukemic
ells leads to lower relapse. The KIR ligand incom-
atibility effect in other HLA-mismatched transplan-
ation populations, however, has not been consistently
bserved [9-13].
Because the HLA and KIR gene complexes are
ncoded on chromosomes 6p21 and 19q13, respec-
ively, individuals may have inhibitory KIR for which
hey have no HLA ligand, and, conversely, individuals
ay have HLA ligands for which they have no KIR.
he independent segregation of HLA and KIR genes
resents the situation wherein donor NK activation
an occur when host target cells lack HLA ligands for
nhibitory KIR-expressing NK cells, regardless of the
LA genotype of the NK cell itself; in other words, a
ecipient who is “missing HLA ligand” can trigger
ytotoxicity of donor NK cells. Population frequency
ata demonstrate that, for the inhibitory KIR2DL2/3,
2DL1, and -3DL1 genes, nearly all individuals have a
omplete complement of inhibitory KIR [14-24]. In
ontrast, frequencies of the corresponding HLA class
ligands (HLA-C group 1, -C group 2, or -Bw4),
eviate greatly from 100%. Therefore, recipient ho-
ozygosity for HLA-C group 1, HLA-C group 2, or
LA-Bw6 and therefore lack of KIR ligand for re-
pective donor inhibitory KIRs can be predicted to
ccur not only between HLA-matched recipients and
onors but also between HLA-mismatched pairs.
ven within individuals, the “missing ligand” model las been shown to play a role in autoimmune disease,
iral infection, and pre-eclampsia [25-27].
Recent studies have examined the effect of “miss-
ng HLA ligand” in allogeneic HCT. Compared with
onor-recipient KIR ligand incompatibility, lack of
ecipient HLA ligand for donor inhibitory KIR was
ound to be a better predictor of outcome after HLA-
aploidentical HCT [28]. Another study found that
ack of ligand in the recipient occurred with 63%
requency in HLA-identical T-cell depleted sibling
CT and that missing ligand predicted higher overall
urvival and lower risk for acute leukemia relapse [29].
ost studies have examined the effect of either KIR
igand incompatibility or lack of KIR ligand on trans-
lantation outcome in study populations with limited
ize. We report ﬁndings from a large dataset of the Inter-
ational Histocompatibility Working Group (IHWG) in
CT, a consortium of international transplantation
enters and histocompatibility laboratories (http://
ww.ihwg.org). Results from this study group indicate
hat lack of KIR ligand in patients receiving HLA-
ismatched transplants may be a predictor for pro-
ection from leukemia relapse.
ETHODS
atient Population
In total, 1770 patients receiving myeloablative
onditioning followed by an unrelated HLA-matched
r -mismatched bone marrow or peripheral blood
tem cell HCT for treatment of AML, myelodysplas-
ic syndrome (MDS), chronic myelogenous leukemia
CML), and acute lymphoblastic leukemia (ALL) were
valuated in this study. All had complete donor-recip-
ent HLA-A, -B, -C, DRB1, and DQB1 allele typing
ata and clinical data (date of transplantation, diagno-
is and stage of disease at time of transplantation,
atient age at transplantation, survival status, ie, date
f last follow-up or death, and date of relapse). Patient
nd transplant characteristics are listed in Table 1.
he use of patient information and samples for this
tudy was approved by the institutional review boards
f each of the 22 participating institutions within the
HWG HCT-KIR Component.
ransplantation Procedure and Clinical Definitions
All patients received myeloablative conditioning
ollowed by infusion of T-replete donor stem cells.
isease stage was deﬁned as low risk (CML in ﬁrst
hronic phase), intermediate risk (CML in second
hronic phase or accelerated phase CML; AML or
LL in remission; MDS refractory anemia subtype),
nd high risk (blastic CML; AML or ALL in relapse;
DS refractory anemia with excess blasts and refrac-
ory anemia with excess blasts in transformation). Re-
apse was deﬁned by morphologic or cytogenetic
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K. C. Hsu et al.830vidence of disease in the peripheral blood or bone
arrow. Overall survival was calculated for the inter-
al between date of transplantation and death or date
f last follow-up. For survival analyses, reinduction of
able 1. Patient and Donor Characteristics*
Recipient
with all KIR
Ligands
Present
(n  380)
Recipient
with KIR
Ligands
Absent
(n  822)
n % n %
LL
Remission 54 14 91 11
Relapse 6 2 29 4
ML
Remission 51 13 105 13
Relapse 30 8 59 7
ML
Chronic phase 1 167 44 402 49
Chronic phase 2 14 4 25 3
Accelerated phase 41 11 76 9
Blast crisis 9 2 16 2
DS
RA 1 <1 8 1
RAEB 2 <1 5 <1
RAEBT 5 1 6 <1
isease severity
Low 167 44 402 49
Intermediate 161 42 305 37
High 52 14 115 14
atient/donor gender
M/M 139 37 289 35
M/F 89 23 146 18
F/M 85 22 198 24
F/F 62 16 174 21
Unknown 5 1 15 2
atient/donor ethnicity
Caucasian 328 86 716 87
Asian 4 1 10 1
Other 23 6 34 4
Unknown 25 7 62 8
atient/donor CMV status
Positive/positive 70 18 171 21
Positive/negative 97 26 214 26
Negative/positive 63 16 114 14
Negative/negative 131 34 280 34
Unknown 19 5 42 5
edian patient age 34.5 35.0
umber of HLA mismatches
0 172 45 408 50
1 118 31 237 29
2 53 14 107 13
3 22 6 39 5
4 6 2 22 3
>4 9 2 9 1
Non-JMDP patients and donors. ALL indicates acute lymphoblas-
tic leukemia; AML, acute myelogenous leukemia; CML chronic
myelogenous leukemia; MDS myelodysplastic syndrome; RA,
refractory anemia; RAEB, refractory anemia with excess blasts;
RAEBT, refractory anemia with excess blasts in transformation;
M, male; F, female; CMV, cytomegalovirus.emission was not considered. [IR Ligand Assignment
High-resolution typing of recipient HLA-B and
LA-C alleles was used to segregate patients into the
ollowing KIR ligand groups: HLA-C group 1 alleles
Ser77 and Asn80) recognized by KIR2DL2 and
DL3; HLA-C group 2 alleles (Asn77 and Lys80)
ecognized by KIR2DL1; HLA-Bw4–positive alleles
Arg79, Ile80, Arg83 or Arg79, Thr80, Arg83) recog-
ized by KIR3DL1; and Bw6-positive alleles (Arg79,
sn80, Gly83), which are not known ligands for any
nhibitory KIR. Patients were grouped according to
omozygosity for HLA-C group 1, HLA-C group 2,
r HLA-Bw6. Under the assumption that an individ-
al has a full complement of inhibitory KIRs, patient
omozygosity for HLA-C group 2 indicates lack of
igand for donor inhibitory KIR2DL2 or 2DL3; pa-
ient homozygosity for HLA-C group 1 implies lack
f ligand for donor inhibitory KIR2DL1; and patient
omozygosity for HLA-Bw6 implies lack of ligand for
onor inhibitory KIR3DL1.
tatistical Analysis
Cox regression models were ﬁt to examine the
ssociation of homozygosity for HLA-C group 1,
LA-C group 2, or HLA-Bw6 with hazards of mor-
ality and relapse. All models were adjusted for sever-
ty of disease (categorized as low, intermediate, and
igh), patient age at transplantation, cytomegalovirus
erostatus, number of mismatched HLA alleles where
ppropriate (modeled as a continuous linear variable
apable of taking on a value from 0 to 10), and trans-
lantation center where appropriate (categorized as a
enter contributing to the Japanese Marrow Donor
rogram [JMDP] vs a center not contributing to
MDP). All reported 2-sided P values were estimated
rom the Wald test, and no adjustments were made for
ultiple comparisons. Therefore, P values between .01
nd .05 should be considered as suggestive rather than
onclusive evidence of a difference.
ESULTS
ffect of Donor-Recipient Ethnicity
In total, 1350 patients (76%) were homozygous
or KIR epitopes HLA-C group 1, group 2, or
LA-Bw6 and therefore could be considered to be
acking 1 ligand for donor inhibitory KIR. Of these
atients, 264 (20%) relapsed. Among the 420 patients
ho were heterozygous for the HLA-C KIR epitopes
nd HLA-Bw4–positive, and therefore not lacking
IR ligand, 93 relapsed (22%). The adjusted hazard of
elapse among patients lacking a ligand was not sta-
istically signiﬁcantly different from that among pa-
ients in whom all ligands were present (hazard ratio
HR], 0.89; 95% conﬁdence interval [CI], 0.70-1.14;
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KIR Ligands and HCT Relapse 831 .37). Because analysis of KIR epitopes is based on
LA genotypes and frequencies of HLA alleles can
ary dramatically between ethnically different popula-
ions, we examined the dependence of the KIR ligand
ffect on ethnicity, where ethnicity was modeled based
n transplantation center. The distribution of KIR
pitope homozygosity and the percentage of patients
ho relapsed in each of the categories differed be-
ween transplant pairs contributed by the JMDP and
ther centers and registries (non-JMDP; Table 2).
hese disparities in KIR epitope distribution could
argely be attributed to the high prevalence of HLA-C
roup 1 allele homozygosity in the Japanese popula-
ion, leading to an over-representation of patients who
acked HLA-C group 2 ligand for donor KIR2DL1.
he small number of JMDP patients who were not
omozygous for HLA-C group 1 precluded an infor-
ative analysis of the effect of a missing KIR ligand in
his group, and therefore all subsequent analyses of
IR ligand effects were restricted to the non-JMDP
opulation.
ffects of Degree of HLA Mismatch and KIR
igand Homozygosity in Non-JMDP Transplants
The adjusted hazard of relapse among patients
issing a KIR ligand was not statistically signiﬁcantly
ifferent from that among patients not missing a KIR
igand among patients in the non-JMDP group (HR,
.84; 95% CI, 0.65-1.09; P  .19). However, there
as evidence to suggest that the effect of a missing
igand differed among patients matched for all 10
LA-A, -B, -C, DRB1, and DQB1 alleles compared
ith those mismatched for 1 allele (P  .009). In
articular, the adjusted hazard of relapse was slightly
igher in the matched group among patients missing
KIR ligand than among those who were not (89 of
09 [22%] relapses among patients missing a ligand vs
1 of 172 [18%] relapses among patients not missing
ligand; Figure 1A; HR, 1.26; 95% CI, 0.83-1.90,
 .27). In contrast, among patients mismatched for
1 HLA-A, -B, -C, DRB1, or DQB1 allele, the ad-
usted hazard of relapse was statistically signiﬁcantly
ower among those missing a ligand than among those
ot missing a ligand (77 of 415 [19%] relapses among
able 2. Distribution of KIR Epitope Homozygosity by Transplantation
HLA Genotype KIR Ligand Absence
LA-C group 1, HLA-C group 2,
and HLA-Bw4 None
LA-C group 2 and HLA-Bw4 HLA-C group 1
LA-C group 1 and HLA-Bw4 HLA-C group 2
LA-Bw6 HLA-Bw4
LA-C group 2 and HLA-Bw6 HLA-C group 1 and HLA-
LA-C group 1 and HLA-Bw6 HLA-C group 2 and HLA-atients missing a ligand vs 58 of 208 [28%] relapses dmong patients not missing a ligand; Figure 1B; HR,
.61; 95% CI, 0.43-0.85; P  .004). Although the
ecrease in the hazard of relapse was greatest among
LA-C group 1 homozygous patients, other groups
lso experienced less relapse than the group not miss-
ng a ligand (Table 3), and the difference between
atients homozygous for HLA-C group 1 and patients
Non-JMDP JMDP
n (%) Relapse (%) n (%) Relapse (%)
380 (32) 89/380 (23) 40 (7) 4/40 (10)
140 (12) 34/140 (24) 2 (<1) 0/2 (0)
203 (17) 42/203 (21) 319 (56) 63/319 (20)
167 (14) 34/167 (20) 33 (6) 5/33 (15)
16 (1) 3/16 (19) 1 (<1) 0/1 (0)
296 (25) 53/296 (18) 173 (30) 30/173 (17)
igure 1. Probability of relapse in HLA-matched (A) or HLA-
ismatched (B) patients lacking KIR ligand (broken line) or not
acking KIR ligand (solid line). Lack of recipient KIR ligand wasCenter
Bw4eﬁned as HLA-C group 1, group 2, or Bw6 homozygosity.
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K. C. Hsu et al.832n the other missing ligand groups was not statistically
igniﬁcant (P  .33).
Although lack of ligand was associated with a sta-
istically signiﬁcantly lower hazard of relapse among
atients who received transplants from an HLA-
ismatched donor, there was no effect seen on over-
ll survival (HR, 0.91; 95% CI, 0.73-1.12; P  .36).
n the HLA-matched group, there was no effect of
ack of KIR ligand on relapse or survival even when
nalyzed within speciﬁc epitope groups (data not
hown).
ffect of Missing KIR Ligand within Disease
roups of the Non-JMDP Dataset
Recent studies have demonstrated a missing KIR
igand effect in AML, but not in CML or ALL in
-cell–depleted HLA-matched transplants [29]. We
herefore compared the effect of missing KIR ligand
n relapse in patients between these disease groups.
mong HLA-mismatched transplants in the present
tudy, the effect of missing a KIR ligand on relapse
as similar among patients with AML (Figure 2A;
R, 0.62; 95% CI, 0.34-1.10; P  .10) and those with
ML (HR, 0.66; 95% CI, 0.39-1.12; P  .12) and
LL (HR, 0.66; 95% CI, 0.39-1.02; P  .06;
igure 2B; combined HR, 0.59; 95% CI, 0.38-0.91;
 .02). A formal test of interaction between disease
AML vs CML or ALL) and missing ligand yielded
 .95.
ontribution of Specificity and Degree of HLA
ismatch to Missing KIR Ligand Effect
n Non-JMDP Transplants
Among the 622 donor-recipient pairs mismatched
or 1 HLA-A, -B, -C, DRB1, or DQB1 allele, 355
57.1%) were single-allele mismatched, 160 (25.7%)
ere 2-allele mismatched, and 107 (17.2%) were mis-
atched for 3 alleles. There was no evidence that
he effect of missing ligand was dependent on the
umber of mismatched alleles (P  .26, test for inter-
ction between number of mismatches and presence
f missing ligand). The effect of missing ligand on the
azard of relapse was also similar across the various
able 3. Effect of Missing KIR Ligand on Relapse in
LA-Mismatched Patients
KIR Ligand Absence HR 95% CI P
one (n  208) 1 — —
LA-C group 1 (n  70) 0.85 0.49–1.48 .56
LA-C group 2 (n  122) 0.47 0.28–0.79 .004
LA-Bw4 (n  90) 0.56 0.33–0.97 .04
LA-Bw4 and HLA-C group 1
(n  13) 0.89 0.28–2.86 .85
LA-Bw4 and HLA-C group 2
(n  119) 0.64 0.39–1.06 .08egrees of HLA allele mismatching. When the study ras restricted to single-allele mismatches only, a sim-
lar conclusion was obtained (data not shown).
omparison of Missing KIR Ligand and KIR Ligand
ncompatibility in Non-JMDP Transplants
In 428 HLA-B and/or HLA-C mismatched pairs,
he KIR ligand incompatibility model and the missing
IR ligand model could be compared directly. There
as no statistically signiﬁcant difference in relapse
etween the 189 patients who could be characterized
y KIR ligand incompatibility in the GVH direction
nd the 239 KIR ligand compatible patients (HR,
.16; 95% CI, 0.76-1.78; P  .48). In the same group
f HLA-B and/or -C mismatched patients, the 276
atients who were missing a KIR ligand had a lower
azard of relapse compared with the 152 patients who
ere not missing a ligand, although it did not reach
igure 2. Probability of relapse in leukemia patients lacking (bro-
en line) or not lacking (solid line) KIR ligand. A. Effect of missing
igand in AML. B. Effect of missing ligand in CML and ALL. The
elative difference in the probability of relapse between the missing
nd non-missing groups was comparable in the AML and non-AML
roups, even though the absolute difference in probabilities was
arger in the AML group due to a higher overall probability of
elapse.
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KIR Ligands and HCT Relapse 833tatistical signiﬁcance (HR, 0.70; 95% CI, 0.46-1.06;
 .09). KIR ligand incompatible donor-recipient
airs who also lacked KIR ligands demonstrated a
ecreased hazard for relapse compared with KIR
igand incompatible pairs who did not lack ligands
HR, 0.59; 95% CI, 0.33-1.05; P  .07). Neither KIR
igand incompatibility nor missing ligand conferred a
urvival beneﬁt (data not shown).
ISCUSSION
Clinical experience demonstrates that the stage of
isease at the time of allogeneic transplantation is a
trong predictor of disease recurrence [4-6]. The
vailability of other measurements for predicting the
isk of post-transplantation relapse could enable trans-
lantation clinicians to tailor the transplantation pro-
edure to individual patient risk and more effectively
lan post-transplantation preventive measures and
onitoring strategies. By using recipient homozygos-
ty for HLA-C group 1, group 2, and Bw6 as markers
or KIR ligand absence, we found a beneﬁcial effect of
issing recipient ligand on the risk of post-transplan-
ation leukemia relapse in patients receiving HLA-
ismatched unrelated donor transplants.
Although the beneﬁcial effect of KIR ligand ab-
ence was seen in recipients of HLA-mismatched al-
ografts, there was no apparent association between
he locus speciﬁcity of HLA mismatch and the effect
f lack of KIR ligand in the recipient. This was some-
hat surprising, because it might be expected that
peciﬁc mismatches at the HLA-B and HLA-C loci
ould potentiate KIR-driven effects through a cell-
urface cis-mediated KIR-HLA mechanism [30] or
hrough lack of engagement of licensed KIR [31,32].
arger sample sizes may be needed to elucidate the
LA locus mismatches most relevant to KIR-medi-
ted alloreactivity. A previous report found that recip-
ents expressing an HLA-C group 1 allele had a higher
verall survival compared with recipients homozygous
or HLA-C group 2 in HLA-identical sibling HCT
or various myeloid malignancies, but the survival ad-
antage could not speciﬁcally be demonstrated to be
ue to lower relapse [33]. A more recent study of 111
atients who received an unrelated allograft for the
reatment of various hematologic malignancies also
emonstrated a deleterious effect of HLA-C group 2
omozygosity on survival [34]. The present IHWG
ataset provides a large number of patients with com-
lete 5-locus HLA allele typing information with
hich to analyze ligand effects in the matched and
ismatched settings. In this dataset, we demonstrate
hat recipient homozygosity for HLA-C group 1 and
LA-Bw6 each confers a statistically signiﬁcant de-
reased risk for relapse and that homozygosity for
LA-C group 2 does not have a deleterious effect on dutcome. The magnitude of the protective effect on
elapse appears largest in the group homozygous for
LA-C group 1 (and therefore lacking the HLA-C
roup 2 ligand). Differences in binding afﬁnity be-
ween the inhibitory KIRs and their HLA ligands are
nown, with KIR2DL1 exhibiting the strongest afﬁn-
ty for its ligand HLA-C group 2 when compared with
he other inhibitory receptors and their ligands
35,36]. It is therefore possible that absence of HLA-C
roup 2 ligand for its high-afﬁnity inhibitory KIR
eads to the most robust release from NK inhibition
nd therefore the highest potential for NK activation.
NK effects against AML have previously been
emonstrated; however, effects against CML and
LL have been less clear [7-9,29,33]. In this analysis,
here was a nearly identical association between lack of
IR ligand and relapse seen among patients with
ML relative to patients with CML or ALL, even
fter adjusting for severity of disease. Although the
otal patient material demonstrated a statistically sig-
iﬁcant effect on relapse, segregation into disease cat-
gories resulted in patient numbers insufﬁcient to
each statistical signiﬁcance. Deﬁnitive conclusions
egarding the effect of KIR ligands in disease-speciﬁc
roups will require even larger numbers of patients in
uture studies.
This study identiﬁed a beneﬁcial effect of recipient
IR epitope homozygosity in lowering risk of relapse,
ut a corresponding effect on survival was not ob-
erved. This may be due to the increased morbidity
nd mortality associated with mismatched unrelated
CT in which GVH disease is more prevalent. In
ddition, the missing ligand effect was seen in HLA-
ismatched transplants and not in HLA-matched
ransplants. The favorable effect of lack of KIR ligand
reviously reported in HLA-identical transplants was
pparent in the setting of ex vivo allograft T-cell
epletion [29], a manipulation that may enhance NK
unction [8]. A recent study examining KIR reconsti-
ution after unrelated donor HCT demonstrated a
orrelation between the presence of donor T cells in
he allograft and lower NK KIR expression, which was
ssociated with inferior survival [37]. Although our
tudy population was restricted to T-cell–replete
ransplants, insufﬁcient data existed to adjust the anal-
sis for the degree of post-transplantation immuno-
uppression, the increased use of which in HLA-mis-
atched transplants may promote NK alloreactivity
hrough T-cell suppression. An alternative explana-
ion for the missing KIR ligand effect in HLA-dispar-
te HCT is the possibility that donor-derived cyto-
oxic T-cell clones expressing inhibitory KIR are
ontributing to the observed antileukemic effect, and
heir expansion may be ampliﬁed in the HLA-dispar-
te setting [13,38,39]. In minimally T-cell–depleted
LA-nonidentical transplants, T-cell alloreactivity
ominates NK reactivity [13]. In this analysis, rates of
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K. C. Hsu et al.834VH disease were comparable between the HLA-
atched and -mismatched groups (73% vs 75% for
rades 2-4 and 35% vs 37% for grades 3-4). Even if
he T- or NK-lymphocyte subsets contributed to the
ower relapse rates observed in this study, the antile-
kemic effect appears to be related speciﬁcally to lack
f recognition of KIR ligands and not to T-cell al-
orecognition of mismatched non-KIR epitope HLA
lleles. It is therefore unlikely that T-cell allorecogni-
ion and GVH disease are responsible for the missing
IR ligand effect on relapse seen in the HLA-mis-
atched group.
This analysis supports the use of recipient HLA
enotyping for the prediction of inhibitory KIR-
ediated NK effects, with lack of KIR ligand being
tatistically associated with lower rates of relapse,
hereas KIR ligand incompatibility is not. Therefore,
he analysis does not support the deliberate selection
f HLA-C or -B mismatched donors to capture KIR
igand incompatibility effects. The importance of con-
idering the known ethnic differences in HLA class I
nd KIR gene and allele frequencies was demonstrated
n this study. Due to these differences, the effect of
issing KIR ligand could be tested only in the non-
MDP population, because the available JMDP data
esulted in some ligand groups too small for meaning-
ul comparisons. A larger JMDP dataset with sufﬁ-
ient numbers of study group members is currently
eing analyzed (Y. Morishima, personal communica-
ion). Correlation of donor KIR genotyping with
CT outcome will certainly be necessary to achieve a
ore comprehensive understanding of NK effects in
CT. The activating KIRs, whose ligands remain
nclear, also likely contribute to transplantation out-
ome: donor activating KIRs have been associated
ith decreased relapse [40] and decreased cytomega-
ovirus activation [41]. Until more information is
nown about the clinical signiﬁcance of donor KIR
eceptor allele diversity and the role of activating
IRs and their ligands, recipient KIR epitope ho-
ozygosity may serve as an important prognostic tool
n aiding the selection of preventive and treatment
ptions for patients with leukemia.
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